Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- WNC -9%, TSLA -8.5%, BXMT -6.1%, ROP -5.2%, LII -5.1%, EWBC -5%, FCF -4.9%, DB -4.9%, OTIS -4.3%, GOOG -3.6%, CNI -3.5%, V -3.3%, HCSG -3.1%, CSGP -3%, IP -2.9%, TNL -2.8%, VBTX -2.3%, VRT -2.2%, WFRD -2.1% (also authorizes new $500 mln share repurchase program; initiates dividend), VICR -1.4%, COF -1.4% (also reports June card metrics), PFSI -1.4% (also increases dividend), NBHC -1.3%, RRR -1.3%, TECK -1.3%, TSEM -1.3%, CME -1.2%, FTV -1.1%, GD -1%, TMO -0.9%, BDN -0.8%, GPI -0.8%
Other news:
- SAGE -26.6% (SAGE Therapeutics and Biogen (BIIB) announce topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 as a potential treatment in essential tremor)
- VSTM -24.8% (prices $55.0 million public offering of common stock, warrants and pre-funded warrants)
- SFL -9.5% (priced its previously announced underwritten public offering of 8,000,000 of the company's common shares, at $12.50/share)
- GERN -6.9% (Chief Commercial Officer to depart)
- ALGM -5.3% (25 mln share offer, wherein funds will be used to repurchase shares from majority shareholder, Sanken Electric; files mixed shelf and files for common stock offering by selling shareholders; also provides guidance)
- RIVN -3.6% (in sympathy with TSLA earnings)
- ATKR -3.4% (CFO to depart, names new CFO)
- LCID -3.3% (in sympathy with TSLA earnings)
- META -2.1% (in sympathy with GOOG earnings)
- SNAP -2% (in sympathy with GOOG earnings)
- TLRY -1.6% (announces another milestone achievement in medical cannabis in Europe)
- GOEV -1.4% (files mixed shelf securities offering)
- PINS -1.2% (in sympathy with GOOG earnings)
- VZLA -1.1% (delivers exceptional economics for Panuco in preliminary economic assessment)
Analyst comments:
- ULTA -1.9% (downgraded to Neutral from Overweight at Piper Sandler)
- GM -1.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- TFC -1% (downgraded to Neutral from Buy at Citigroup)